Fidelity Investments
LABP

Fidelity Investments’s Landos Biopharma, Inc. Common Stock LABP Stock Holding History

Fidelity Investments’s Portfolio LABP Stock Details LABP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-200
Closed -$1K – 5612
2022
Q4 		$1K Hold
200
– – ﹤0.01% 4656
2022
Q3 		$1K Buy
200
+4
+2% +$35 ﹤0.01% 4781
2022
Q2 		$1K Buy
196
+58
+42% +$528 ﹤0.01% 4846
2022
Q1 		$2K Buy
+138
New +$3.51K ﹤0.01% 4739

Other funds holding LABP

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments's LABP Position: Q1 2023 in Review

Fidelity Investments sold out of Landos Biopharma, Inc. Common Stock (LABP) in Q1 2023, closing a stake of 200 shares — an estimated $1K sold.

Fidelity Investments first reported a position in LABP in Q1 2022 and held it in 4 quarters. The position peaked at $2K in Q1 2022. 20 funds tracked by Wall St. Rank hold LABP as of Q1 2023.

  • Fidelity Investments reported no remaining Landos Biopharma, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Fidelity Investments sold 200 Landos Biopharma, Inc. Common Stock shares in Q1 2023, an estimated $1K.
  • Fidelity Investments first reported a position in Landos Biopharma, Inc. Common Stock in Q1 2022 and held it in 4 quarters.
  • Fidelity Investments's Landos Biopharma, Inc. Common Stock position peaked at $2K in Q1 2022.
  • 20 funds tracked by Wall St. Rank held Landos Biopharma, Inc. Common Stock as of Q1 2023.

Based on Fidelity Investments's 13F filing for Q1 2023, filed 11 May 2023.